Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis

NCT00439647 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1199

Last updated 2017-04-21

Study results available
· View outcomes & findings →

Summary

This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.

Conditions

  • Male Osteoporosis

Interventions

DRUG

Zoledronic acid 5 mg iv

Zoledronic acid 5 mg iv given once a year.

DRUG

Placebo

Placebo intravenous (i.v.) once a year

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Argentina

  • Novartis Pharmaceuticals · Novartis Belgium

  • Novartis Pharmaceuticals · Novartis Brazil

  • Novartis Pharmaceuticals · Novartis Czech Republic

  • Novartis Pharmaceuticals · Novartis Denmark

  • Novartis Pharmaceuticals · Novartis Finland

  • Novartis Pharmaceuticals · Novartis Germany

  • Novartis Pharmaceuticals · Novartis Hungary

  • Novartis Pharmaceuticals · Novartis Norway

  • Novartis Pharmaceuticals · Novartis Portugal

  • Novartis Pharmaceuticals · Novartis Romania

  • Novartis Pharmaceuticals · Novartis Spain

  • Novartis Pharmaceuticals · Novartis Slovakia

  • Novartis Pharmaceuticals · Novartis Sweden

  • Novartis Pharmaceuticals · Novartis

  • Novartis Pharmaceuticals · Novartis United Kingdom

  • Novartis Pharmaceuticals · Novartis Australia

  • Novartis Pharmaceuticals · Novartis Italy

  • Novartis Pharmaceuticals · Novartis Austria

  • Novartis Pharmaceuticals · Novartis Iceland

  • Novartis Pharmaceuticals · Novartis Poland

  • Novartis Pharmaceuticals · Novartis Russia

  • Novartis Pharmaceuticals · Novartis (South Africa)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Czechia
  • Denmark
  • Finland
  • Germany
  • Hungary
  • Iceland
  • Italy
  • Norway
  • Poland
  • Portugal
  • Romania
  • Russia
  • Slovakia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439647 on ClinicalTrials.gov